Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?
Abstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissu...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | Stem Cell Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13287-017-0695-y |
id |
doaj-158d248adc154b25b17c05aa0ccb5e86 |
---|---|
record_format |
Article |
spelling |
doaj-158d248adc154b25b17c05aa0ccb5e862020-11-25T00:43:16ZengBMCStem Cell Research & Therapy1757-65122017-10-018111110.1186/s13287-017-0695-yMesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?Santiago Roura0Carolina Gálvez-Montón1Clémentine Mirabel2Joaquim Vives3Antoni Bayes-Genis4ICREC Research Program, Germans Trias i Pujol Health Research InstituteICREC Research Program, Germans Trias i Pujol Health Research InstituteServei de Teràpia Cel∙lular, Banc de Sang i TeixitsServei de Teràpia Cel∙lular, Banc de Sang i TeixitsICREC Research Program, Germans Trias i Pujol Health Research InstituteAbstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.http://link.springer.com/article/10.1186/s13287-017-0695-yCardiac adipose tissueCardiac repairCell therapyGood manufacturing practiceMesenchymal stem cellsTissue engineering |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Santiago Roura Carolina Gálvez-Montón Clémentine Mirabel Joaquim Vives Antoni Bayes-Genis |
spellingShingle |
Santiago Roura Carolina Gálvez-Montón Clémentine Mirabel Joaquim Vives Antoni Bayes-Genis Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? Stem Cell Research & Therapy Cardiac adipose tissue Cardiac repair Cell therapy Good manufacturing practice Mesenchymal stem cells Tissue engineering |
author_facet |
Santiago Roura Carolina Gálvez-Montón Clémentine Mirabel Joaquim Vives Antoni Bayes-Genis |
author_sort |
Santiago Roura |
title |
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
title_short |
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
title_full |
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
title_fullStr |
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
title_full_unstemmed |
Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
title_sort |
mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? |
publisher |
BMC |
series |
Stem Cell Research & Therapy |
issn |
1757-6512 |
publishDate |
2017-10-01 |
description |
Abstract For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials. |
topic |
Cardiac adipose tissue Cardiac repair Cell therapy Good manufacturing practice Mesenchymal stem cells Tissue engineering |
url |
http://link.springer.com/article/10.1186/s13287-017-0695-y |
work_keys_str_mv |
AT santiagoroura mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario AT carolinagalvezmonton mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario AT clementinemirabel mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario AT joaquimvives mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario AT antonibayesgenis mesenchymalstemcellsforcardiacrepairaretheactorsreadyfortheclinicalscenario |
_version_ |
1725279448088969216 |